Presentation
4 March 2022 Multiplexed bio-assay for a reliable detection of HER2 in human plasma using a combined label-free/fluorescence biosensing platform
Author Affiliations +
Abstract
Human epidermal growth factor receptor 2 (HER2) over-expression occurs in 15–20% of breast cancers and it is generally associated with a dismal prognosis. In this work, we report on the use of one-dimensional photonic crystal biochips to detect clinically relevant concentrations of HER2 in human plasma samples. To this aim, we optimized an optical read-out system, combining both label-free and fluorescence detection, which makes use of biochips tailored with specific proteins for specific biological recognition. Our biochips were used to discriminate HER2 positive/negative human plasma samples providing a solid and reliable tool for clinical diagnostics.
Conference Presentation
© (2022) COPYRIGHT Society of Photo-Optical Instrumentation Engineers (SPIE). Downloading of the abstract is permitted for personal use only.
Tommaso Pileri, Alberto Sinibaldi, Matteo Allegretti, Norbert Danz, Peter Munzert, Elena Giordani, Agostino Occhicone, Frank Sonntag, Patrizio Giacomini, and Francesco Michelotti "Multiplexed bio-assay for a reliable detection of HER2 in human plasma using a combined label-free/fluorescence biosensing platform", Proc. SPIE PC11979, Frontiers in Biological Detection: From Nanosensors to Systems XIV, PC1197903 (4 March 2022); https://doi.org/10.1117/12.2623466
Advertisement
Advertisement
KEYWORDS
Plasma

Biosensing

Multiplexing

Breast cancer

Cancer

Oncology

Proteins

Back to Top